MOA - Bleeding Flashcards Preview

Pharm 3 > MOA - Bleeding > Flashcards

Flashcards in MOA - Bleeding Deck (21)
Loading flashcards...
1
Q

Inhibits Vit K cofactors to synth Vit K which effects Factors II, VII, IX, X & protein C/S

A

Warfarin

2
Q

W/in 5 min of IV infusion forms stable salt complex in the presence of heparin and the anticoagulant activity is lost

A

Protamine Sulfate

3
Q

Binds ATIII and selectively inhibits/neutralizing Factor Xa

A

Fondaparinux

4
Q

Fat Soluble Vit-K

A

Phytonadione

5
Q

Enzyme synth by kidney that converts uncomplexed plasminogen to plasmin which degrades fibrin and clotting factors V and VII

A

Thrombolytic Enzymes

6
Q

Binds AT-III = speeds up AT-III ability to inhibit thrombin & other factors.

A

UFH - req aPTT monitoring

7
Q

Dissolve clots by converting plasminogen to plasmin which hydrolyzes fibrin thus lysing thrombus

A

Fibrinolytics / Thrombolytics (IV)

8
Q

Reversibly inhibits fibrin binding to GPIIb/IIIa receptors. w/out monoclonal antibodies. (not immunogenic)

A

Eptifibatide (IV)

Tirofiban (IV)

9
Q

Binds directly to free/clot-bound thrombin (factor IIa) active site which inhibits thrombin downstream effects.
-Prevents Fibrinogen to Fibrin conversion

A

Direct Thrombin Inhibitors

  • Bivalirudin
  • Argatroban
  • Dabigatran - Prodrug
10
Q

Reversibly inhibits PLT aggregation by inhibiting Adenosine binding to P2Y-12 Receptor which inhibits GPIIb/IIIa receptors

A

Ticagrelor (PO)

11
Q
  • Inhibits cAMP breakdown = increase in cAMP causes less SVR=(V-dil)
  • Reversibly inhibits platelet aggregation
A

Cilostazol (Pletal) PO

12
Q
  • Irreversibly inhibits COX-1 and 2 = decreased TXA2 synthesis from arachidonic acid
  • Also to a lesser extent inhibits prostacyclin activity in endothelial cells.
A

Aspirin

13
Q

Monoclonal antibody fragment binds dabigatran with higher affinity then thrombin neutralizing it

A

Idarucizumab (IV)

14
Q
  • Inactivates factor Xa

- Also binds AT-III w/ less affinity

A

LMWH - does not need aPTT test

15
Q

Irreversibly inhibits PLT aggregation by inhibiting Adenosine binding to P2Y-12 Receptor which inhibits GPIIb/IIIa receptors.

A

Clopodogrel (PO)

Prasugrel (PO)

16
Q

Activates plasminogen bound to fibrin in a thrombus, which initiates fibrinolysis

A

Tissue Plasminogen Activators (tPA)

17
Q

Prevents fibrin, vWF, and other contents from binding to PLT’s by monoclonal antibody fragments hindering GPIIb/IIIa receptors.

A

Abciximab (IV)

18
Q

Forms a reversible complex that displaces plasminogen from fibrin and inhibits fibrinolysis
-Also inhibits proteolytic activity of plasmin

A

Tranexamic Acid

19
Q
  • Stimulates prostacyclin synthesis
  • Inhibits the uptake of adenosine into (PLT’s, RBC’s, endothelial cells) = Increased Adenosine Conc then stimulates cAMP which inhibits PLT aggegration
A

Dipyridamole (Persantine) PO/IV

20
Q

Prevents prothrombin to thrombin w/ no effect on PLT’s by selectively blocking factor Xa.
- no co-factor AT-III req for activity

A

Direct Oral Factor Xa Inhibitors

21
Q

Inhibits ADP binding to P2Y-12 receptior which inhibits GPIIb/IIIa receptors.

A

Cangrelor (IV)